|
Volumn 15, Issue 12, 2010, Pages 1335-1343
|
The European medicines agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: Summary of the scientific assessment of the European medicines agency committee for medicinal products for human use
|
Author keywords
Chronic lymphocytic leukemia; CLL; EMA; European medicines agency; Ofatumumab
|
Indexed keywords
ALEMTUZUMAB;
CD20 ANTIBODY;
CD20 ANTIGEN;
COMPLEMENT COMPONENT C3A;
COMPLEMENT COMPONENT C4A;
COMPLEMENT COMPONENT C5A;
FLUDARABINE;
OFATUMUMAB;
RITUXIMAB;
AGRANULOCYTOSIS;
ANAPHYLAXIS;
ANEMIA;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIGEN EXPRESSION;
AREA UNDER THE CURVE;
BACKACHE;
BLOOD CLOTTING DISORDER;
BLOOD DISEASE;
BRONCHOSPASM;
CANCER SURVIVAL;
CHILL;
CHRONIC LYMPHATIC LEUKEMIA;
COMPLEMENT DEPENDENT CYTOTOXICITY;
CONNECTIVE TISSUE DISEASE;
COUGHING;
CREATININE CLEARANCE;
CYTOKINE PRODUCTION;
CYTOKINE RELEASE SYNDROME;
CYTOLYSIS;
CYTOLYTIC HEPATITIS;
DIARRHEA;
DISTRIBUTION VOLUME;
DOSE RESPONSE;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG ERUPTION;
DRUG FEVER;
DRUG HALF LIFE;
DRUG HYPERSENSITIVITY;
DRUG MEGADOSE;
DRUG RESPONSE;
DRUG SURVEILLANCE PROGRAM;
DRUG WITHDRAWAL;
DYSPNEA;
ERYTHROCYTE APLASIA;
FATIGUE;
FEBRILE NEUTROPENIA;
GASTROINTESTINAL DISEASE;
HEART DISEASE;
HERPES VIRUS INFECTION;
HOT FLUSH;
HUMAN;
HYPERHIDROSIS;
HYPERTENSION;
HYPOTENSION;
HYPOXIA;
IMMUNOPATHOLOGY;
INFECTION;
INFESTATION;
INJECTION SITE REACTION;
LEUKOPENIA;
LIPID RAFT;
LOWER RESPIRATORY TRACT INFECTION;
LYMPHATIC SYSTEM DISEASE;
LYMPHOCYTOPENIA;
MAXIMUM PLASMA CONCENTRATION;
MEDIASTINUM DISEASE;
METABOLIC DISORDER;
MUSCULOSKELETAL DISEASE;
NAUSEA;
NEUTROPENIA;
NIGHT SWEAT;
NONHUMAN;
NOSE CONGESTION;
NUTRITIONAL DISORDER;
OVERALL SURVIVAL;
PNEUMONIA;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PRURITUS;
RECOMMENDED DRUG DOSE;
RESPIRATORY TRACT DISEASE;
REVIEW;
RIGOR;
RISK BENEFIT ANALYSIS;
SEPSIS;
SEPTIC SHOCK;
SIDE EFFECT;
SKIN DISEASE;
SMALL INTESTINE OBSTRUCTION;
SOFT TISSUE DISEASE;
SORE THROAT;
SURVIVAL TIME;
TACHYCARDIA;
THORAX DISEASE;
THORAX PAIN;
THROMBOCYTOPENIA;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TUMOR LYSIS SYNDROME;
UPPER RESPIRATORY TRACT INFECTION;
URTICARIA;
VASCULAR DISEASE;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTIGENS, CD20;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DRUG RESISTANCE, NEOPLASM;
EUROPEAN UNION;
FEMALE;
HEALTH SERVICES;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
MALE;
NEOPLASM STAGING;
PRACTICE GUIDELINES AS TOPIC;
SURVIVAL RATE;
TREATMENT OUTCOME;
VIDARABINE;
|
EID: 78650980278
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2010-0255 Document Type: Review |
Times cited : (20)
|
References (10)
|